Greenland Mines Ltd operates across two segments: natural resources and cell and gene therapy. Its resources arm is focused on exploring for palladium, gold, and platinum, centered on the exploration and development of the Skaergaard project in Southeast Greenland. On the therapeutics side, the company is developing KLTO-202, a gene therapy targeting the treatment and prevention of amyotrophic lateral sclerosis (ALS), and KLTO-101, aimed at treating or preventing Alzheimer's disease, alongside therapies for Parkinson's and other age-related conditions. Previously known as Klotho Neurosciences, Inc., the company adopted its current name in March 2026. It is headquartered in Charlotte, North Carolina.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Other Precious Metals
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 13.35M shares outstanding
USGreenland Mines Ltd operates across two segments: natural resources and cell and gene therapy.
Its resources arm is focused on exploring for palladium, gold, and platinum, centered on the exploration and development of the Skaergaard project in Southeast Greenland. On the therapeutics side, the company is developing KLTO-202, a gene therapy targeting the treatment and prevention of amyotrophic lateral sclerosis (ALS), and KLTO-101, aimed at treating or preventing Alzheimer's disease, alongside therapies for Parkinson's and other age-related conditions. Previously known as Klotho Neurosciences, Inc., the company adopted its current name in March 2026.
It is headquartered in Charlotte, North Carolina.
Joseph A. Sinkule
Founder, CEO, Chairman of the Board & Secretary
Jeffrey LeBlanc
Chief Financial Officer
Peter J. Moriarty
Chief Business Officer
Shalom Z. Hirschman
Medical Advisor & Director
Employees
5
Country
US
Sector
Basic Materials
Website
greenlandmines.com
Loading congressional disclosures…
based on 13.35M shares outstanding
US30d Avg
24.55M
60d Avg
12.35M
90d Avg
8.10M
